WASHINGTON, DC – The Center for Strategic and International Studies (CSIS), a bipartisan, nonprofit policy research organization dedicated to advancing practical ideas to address the world’s greatest ...

Rajamahendravaram: Anaparthi MLA Nallamilli Ramakrishna Reddy has been appointed as the Andhra Pradesh State Convenor for the Special Intensive Revision (SIR) programme being undertaken by the ...

MUMBAI, Feb 25 (Reuters) - Indian drugmaker Dr Reddy's Laboratories (REDY.NS), opens new tab is likely to launch its generic semaglutide injection in the country in March under the brand name Obeda, ...

HYDERABAD, Feb 17 (Reuters) - Indian drugmaker Dr Reddy’s Laboratories (REDY.NS), opens new tab hopes to launch a generic version of Novo Nordisk’s (NOVOb.CO), opens new tab blockbuster weight‑loss ...

The Department of Justice is requiring Reddy Ice LLC to divest assets across five states to resolve antitrust concerns from its planned acquisition of an ice maker backed by private equity firm ...

Reddy Ice, a portfolio company of SCI Capital Partners LP, agreed to buy Arctic Glacier from Carlyle Group. The companies announced the deal on the same day that the Justice Department's antitrust ...

Dr. Reddy's Laboratories (RDY) on Wednesday announced that India’s drug regulator, the Drugs Controller General of India, has issued marketing and manufacturing authorization for a generic version of ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key ...

What are music’s biggest global artist stories of 2025? Here’s a trio for you: Taylor Swift’s record-shattering The Life Of A Showgirl; Bad Bunny’s culture-defining residency in Puerto Rico (and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min AAR's $78M acquisition of HAECO ...

Dr. Reddy’s Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, ...